Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Hepregen Launches First Human HepatoPac™ Assay Kit

Published: Wednesday, March 26, 2014
Last Updated: Wednesday, March 26, 2014
Bookmark and Share
Application-directed kit provides information useful in predicting potential drug-induced liver injury.

At the Society of Toxicology's 53rd Annual Meeting, Hepregen Corporation has announced the commercial launch of the company's first HepatoPacT kit designed specifically for toxicology applications.

The kit contains one or more standard 96-well tissue culture plates featuring specially configured micro-patterned human liver cells co-cultured with stromal cells.

The liver cells (hepatocytes) on these plates mirror the behavior of liver cells in the body, enabling scientists to generate data that can be useful for prediction of toxic responses to chemical agents, including drug candidates.

The application-directed platform also provides a tool for the study of the mechanisms leading to such responses.

Jack McGeehan, Hepregen's Vice President of Operations, stated, "The hepatocytes in this specially configured product remain viable for weeks at a time, and they exhibit full functionality during this extended time period. This longevity means that the product may be useful for the study of chronic exposure to drug candidates and other new chemical entities, reflecting what likely could occur when humans are exposed to such agents for long periods. Because the hepatocytes also are fully active metabolically, investigators can evaluate toxicity associated with metabolites of these chemical entities in a single experiment."

Dr. Vincent Zurawski, Hepregen's Chief Executive Officer, stated, "This new kit is the first version of a human HepatoPacT application-directed kit that is focused on the in vitro toxicology market. In the coming months, aiming to serve this growing market, Hepregen also expects to be introducing more advanced HepatoPacT toxicology products, some of which are currently in development. The launch adds another product to the company's portfolio, which includes human, rat, monkey, human triple-donor and rat-human HepatoPacT application-directed kits for metabolite identification and profiling, and a recently introduced human kit to evaluate metabolic stability."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

QTS and Hepregen Execute Co-Development and Co-Marketing Agreement
Agreement provides for development, manufacture and sale of HepatoPac® B-CLEAR® co-labeled proprietary products for liver transporter analysis.
Tuesday, November 04, 2014
Scientific News
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
Electrical Control of Cancer Cells
Research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) has revealed a new electrical mechanism that can control these switches.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
Structural Discoveries Could Aid in Better Drug Design
Scientists have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output.
Determining the Age of Fingerprints
Watch the imprint of a tire track in soft mud, and it will slowly blur, the ridges of the pattern gradually flowing into the valleys. Researchers have tested the theory that a similar effect could be used to give forensic scientists a way to date fingerprints.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!